|
Croatia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Croatia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Croatia.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Croatian pharmaceutical and healthcare industry.
Competitive intelligence, Croatian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Croatian market.
The Croatia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Croatia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Croatian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Croatia to test other views – a key input for successful budgeting and strategic business planning in the Croatian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Croatian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Croatia.
- Exploit The Latest Competitive Croatian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Croatia.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Croatia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Croatia Pharmaceuticals Industry SWOT |
| Croatia Political SWOT |
| Croatia Economic SWOT |
| Croatia Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Croatia – Market Summary |
| Regulatory Regime |
| Table: Croatian Product Approvals, 2006 |
| Intellectual Property Regime |
| Pricing Regime |
| Reimbursement Regime |
| Recent Pricing And Reimbursement Developments |
| Table: Recently Approved Medicines In Croatia |
Chapter - Industry Trends And Developments |
| Epidemiology |
| Table: Leading Causes Of Death In Croatia, 2005 |
| Healthcare Provision |
| Healthcare Expenditure |
| Healthcare Debts |
| Healthcare Reform |
| Domestic Pharmaceutical Industry |
| Domestic Company Activity |
| Foreign Company Activity |
| Table: Lukaps' Time Line |
| Pharmaceutical Retail |
| Research And Development Sector |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Croatia – Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Croatia – Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Croatia - Economic Activity |
| Prescription Market Forecast |
| Table: Croatia – Prescription Market Indicators, Historical Data and Forecasts (HRKmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Croatia – Patented Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: Croatia – Generics Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: Croatia – OTC Market Indicators, Historical Data and Forecasts (HRKmn unless otherwise stated) |
| Export/Import Forecasts |
| Table: Croatia – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Other Healthcare Forecasts |
| Table: Croatia – Other Healthcare Indicators, Historical Data and Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| International Company Profiles |
| GlaxoSmithKline |
| Pfizer |
| Sanofi-Aventis |
| Novartis |
| Merck & Co |
| Krka |
| Indigenous Company Profiles |
| Pliva |
| Belupo |
Chapter - Country Snapshot: Croatia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2000-2003 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 1999-2004 |
| Table: Consumer Expenditure, 2000-2010 (US$) |
| Table: Average Annual Wages, 2000-2010 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Croatia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In the BMI Business Environment Rating matrix for Q209, Croatia is once again in 15th position out of the 20 main markets surveyed in Central and Eastern Europe (CEE). The market was valued at around US$980mn in 2008, somewhat below neighbouring Serbia, which it now also trails in the CEE matrix. By 2013, consumer spending on pharmaceuticals in Croatia is expected to reach US$1.27bn, growing at a modest compound annual growth rate (CAGR) of 6.99% in local currency terms, constrained by the need to eliminate massive healthcare debts, small population numbers, the dominance of generics and the increase in self-financing of medical and pharmaceutical expenses. On the other hand, trading and regulatory regimes should be facilitated by the steady progress towards EU membership, which is likely to be achieved in 2011 or 2012 at the earliest.
In fact, in order to rein in spending, Croatia recently enacted a series of reforms that aim to introduce greater efficiencies, restrict spending over the medium term, find alternative sources of spending and de-monopolise the country’s health insurance sector. The ministry is seeking to increase individual institutions’ accountability for finances, which will be achieved through the recent introduction of the 20% co-insurance fees for medical services in both primary and hospital care. On the other hand, the government is offering a supplementary insurance scheme which would cover all fees for services, in a bid to release pressure on the state insurer. However, BMI notes the introduction of a co-insurance scheme provides significant political risk, given the high number of low-income population and the tradition of socialist-type economy prior to 1991.
On an economic front, with EU membership still on the cards and convergence gains still to be realised, we maintain a positive long-term view for the Croatian economy. Supported by continued market reform and a well-diversified economy, we forecast average annual growth of 3.6% over the course of 2009- 2013, twice the rate of the eurozone. We caution, however, that delayed EU membership or a more protracted and severe recession in 2009 may weigh on Croatia's long-term economic prospects, which will have a significant impact on both state and individual finances available for healthcare and pharmaceutical services.
In the meantime, the domestic drug industry will continue to meet around a third of local demand in terms of value and up to a half in terms of volume, although the dominant Croatian drugmaker Pliva has been in the hand of a major international player – namely US-based Barr – since 2006. The second-largest - but considerably smaller player than Pliva - local drugmaker is Belupo, which continues to expand its range of over-the-counter (OTC) medicines. To this end, in January 2009, Belupo launched its herbal antidepressant Aktivin-H 60 in a new package. The Croatian OTC market is expected to increase its share in the total market from some 21.9% in 2008 to around 23.6% in 2013, reaching the value of US$300mn at consumer prices, which clearly represents a commercial opportunity for Belupo.
|
Croatia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |